PSP-corticobasal syndrome (PSP-CBS) is an atypical variant of progressive supranuclear palsy (PSP), a rare late-onset neurodegenerative disease.
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on PSP-CBS is limited primarily due to its rarity, affecting fewer than 10 individuals per million. This extreme rarity hampers the ability to conduct large-scale clinical studies, resulting in a lack of systematic documentation and understanding of the disease's clinical features and progression. Additionally, the overlap of symptoms with other neurodegenerative disorders complicates the clinical characterization of PSP-CBS.
To navigate your care for PSP-CBS, consider seeking a neurologist who specializes in atypical parkinsonian disorders or neurodegenerative diseases. While there are currently no identified patient organizations specifically for PSP-CBS, you may find resources through broader organizations such as the National Organization for Rare Disorders (NORD) at rarediseases.org. Additionally, inquire about participating in clinical trials or natural history studies, which may provide valuable insights and contribute to ongoing research.
There are currently 21 active clinical trials exploring various aspects of PSP-CBS and related conditions. Notably, several orphan drugs have been designated for this condition, including (2'R,3'S)-2'-hydroxy-N-carboxy-3'-amino-5'-methyl-hexanoic and Anti-eTau Humanized IgG4 Monoclonal Antibody. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=progressive%20supranuclear%20palsy-corticobasal%20syndrome. This research landscape provides hope for future treatment options.
Actionable guidance for navigating care for progressive supranuclear palsy-corticobasal syndrome
To navigate your care for PSP-CBS, consider seeking a neurologist who specializes in atypical parkinsonian disorders or neurodegenerative diseases. While there are currently no identified patient organizations specifically for PSP-CBS, you may find resources through broader organizations such as the National Organization for Rare Disorders (NORD) at rarediseases.org. Additionally, inquire about participating in clinical trials or natural history studies, which may provide valuable insights and contribute to ongoing research.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on PSP-CBS is limited primarily due to its rarity, affecting fewer than 10 individuals per million. This extreme rarity hampers the ability to conduct large-scale clinical studies, resulting in a lack of systematic documentation and understanding of the disease's clinical features and progression. Additionally, the overlap of symptoms with other neurodegenerative disorders complicates the clinical characterization of PSP-CBS.
To navigate your care for PSP-CBS, consider seeking a neurologist who specializes in atypical parkinsonian disorders or neurodegenerative diseases. While there are currently no identified patient organizations specifically for PSP-CBS, you may find resources through broader organizations such as the National Organization for Rare Disorders (NORD) at rarediseases.org. Additionally, inquire about participating in clinical trials or natural history studies, which may provide valuable insights and contribute to ongoing research.
There are currently 21 active clinical trials exploring various aspects of PSP-CBS and related conditions. Notably, several orphan drugs have been designated for this condition, including (2'R,3'S)-2'-hydroxy-N-carboxy-3'-amino-5'-methyl-hexanoic and Anti-eTau Humanized IgG4 Monoclonal Antibody. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=progressive%20supranuclear%20palsy-corticobasal%20syndrome. This research landscape provides hope for future treatment options.
Actionable guidance for navigating care for progressive supranuclear palsy-corticobasal syndrome
To navigate your care for PSP-CBS, consider seeking a neurologist who specializes in atypical parkinsonian disorders or neurodegenerative diseases. While there are currently no identified patient organizations specifically for PSP-CBS, you may find resources through broader organizations such as the National Organization for Rare Disorders (NORD) at rarediseases.org. Additionally, inquire about participating in clinical trials or natural history studies, which may provide valuable insights and contribute to ongoing research.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on PSP-CBS is limited primarily due to its rarity, affecting fewer than 10 individuals per million. This extreme rarity hampers the ability to conduct large-scale clinical studies, resulting in a lack of systematic documentation and understanding of the disease's clinical features and progression. Additionally, the overlap of symptoms with other neurodegenerative disorders complicates the clinical characterization of PSP-CBS.
To navigate your care for PSP-CBS, consider seeking a neurologist who specializes in atypical parkinsonian disorders or neurodegenerative diseases. While there are currently no identified patient organizations specifically for PSP-CBS, you may find resources through broader organizations such as the National Organization for Rare Disorders (NORD) at rarediseases.org. Additionally, inquire about participating in clinical trials or natural history studies, which may provide valuable insights and contribute to ongoing research.
There are currently 21 active clinical trials exploring various aspects of PSP-CBS and related conditions. Notably, several orphan drugs have been designated for this condition, including (2'R,3'S)-2'-hydroxy-N-carboxy-3'-amino-5'-methyl-hexanoic and Anti-eTau Humanized IgG4 Monoclonal Antibody. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=progressive%20supranuclear%20palsy-corticobasal%20syndrome. This research landscape provides hope for future treatment options.
Actionable guidance for navigating care for progressive supranuclear palsy-corticobasal syndrome
To navigate your care for PSP-CBS, consider seeking a neurologist who specializes in atypical parkinsonian disorders or neurodegenerative diseases. While there are currently no identified patient organizations specifically for PSP-CBS, you may find resources through broader organizations such as the National Organization for Rare Disorders (NORD) at rarediseases.org. Additionally, inquire about participating in clinical trials or natural history studies, which may provide valuable insights and contribute to ongoing research.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 2 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.